Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 9 Nov 2026, 22:20 UTC. The headline in use is “Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript”. This note is SignalsMonitor's own briefing, not the publisher's article.